{"title":"Yasser's COVID-19 Discrepancy Phenomenon; A Novel Phenomenon And Effective Regimen; Retrospective-Observational Study","authors":"Y. Elsayed","doi":"10.31579/2690-1919/185","DOIUrl":null,"url":null,"abstract":"Aim of the study: Clarification for the time of the clinical improvement after management COVID-19 pneumonia versus normal gradation of common workup is the target for the current study. Background: COVID-19 pneumonia is a current serious international pandemic infection. Generally, in medical diseases, the clinical response is commonly parallel to laboratory and radiological improvement. This rule may be different in COVID-19 pneumonia. Method of study and patients: The author reported retrospective-observational 47-case report series. The study was conducted in a physician outpatient clinic thorough nearly 12-months, starting from Jun 9, 2020, and, ended on May 8, 2021. All included cases were COVID-19 pneumonia and treated with conventional antibiotics, anticoagulants, and steroids. Results: The mean ±SD age was: 50.08 (14.9) years, with male sex predominance (55.32%). The mean days of clinical versus leukocytosis, neutrophilia, and lymphopenia improvement (0.84 ±0.49, 13.05 ±6.44, 13.05 ±7.01, 13.05 ±7.01).The mean ±SD days of clinical versus CRP, D-dimer, s. ferritin, and LDH improvement (0.84 ±0.49, 12.2 ±3.25, 12.2 ±6.21, 12.3 ±5.46, 20.92± 9.48). The mean days of clinical versus radiological and electrocardiographic improvement (0.84 ±0.49, 15.74 ±5.25, 11.45 ±5.45). The test was statistically significant in all the above tests (p-value is < .00001) Conclusions: Yasser’s COVID-19 Discrepancy phenomenon is a novel descriptive phenomenon that is always seen in all COVID-19 pneumonia. Initial dramatic improvement of the clinical status of COVID-19 pneumonic patient, not a simultaneously after the management, not a coincide with laboratory, radiological, and electrocardiographic workup. Further larger studies for the study medical regimen with considering of “Yasser’s COVID-19 Discrepancy phenomenon” is recommended.","PeriodicalId":93114,"journal":{"name":"Journal of clinical research and reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical research and reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2690-1919/185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim of the study: Clarification for the time of the clinical improvement after management COVID-19 pneumonia versus normal gradation of common workup is the target for the current study. Background: COVID-19 pneumonia is a current serious international pandemic infection. Generally, in medical diseases, the clinical response is commonly parallel to laboratory and radiological improvement. This rule may be different in COVID-19 pneumonia. Method of study and patients: The author reported retrospective-observational 47-case report series. The study was conducted in a physician outpatient clinic thorough nearly 12-months, starting from Jun 9, 2020, and, ended on May 8, 2021. All included cases were COVID-19 pneumonia and treated with conventional antibiotics, anticoagulants, and steroids. Results: The mean ±SD age was: 50.08 (14.9) years, with male sex predominance (55.32%). The mean days of clinical versus leukocytosis, neutrophilia, and lymphopenia improvement (0.84 ±0.49, 13.05 ±6.44, 13.05 ±7.01, 13.05 ±7.01).The mean ±SD days of clinical versus CRP, D-dimer, s. ferritin, and LDH improvement (0.84 ±0.49, 12.2 ±3.25, 12.2 ±6.21, 12.3 ±5.46, 20.92± 9.48). The mean days of clinical versus radiological and electrocardiographic improvement (0.84 ±0.49, 15.74 ±5.25, 11.45 ±5.45). The test was statistically significant in all the above tests (p-value is < .00001) Conclusions: Yasser’s COVID-19 Discrepancy phenomenon is a novel descriptive phenomenon that is always seen in all COVID-19 pneumonia. Initial dramatic improvement of the clinical status of COVID-19 pneumonic patient, not a simultaneously after the management, not a coincide with laboratory, radiological, and electrocardiographic workup. Further larger studies for the study medical regimen with considering of “Yasser’s COVID-19 Discrepancy phenomenon” is recommended.